The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators (Q42641856)

4 November 2017

title

The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators (English)

1 reference

4 November 2017

Kaplan NM

1

1 reference

4 November 2017

publication date

1 July 1996

1 reference

4 November 2017

published in

Clinical Therapeutics

1 reference

4 November 2017

volume

18

1 reference

4 November 2017

issue

4

1 reference

4 November 2017

page(s)

658-670

1 reference

Post marketing surveillance of captopril (for hypertension): a preliminary report

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980216-5

7 January 2021

Postmarketing surveillance of enalapril. I: Results of prescription-event monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980216-5

7 January 2021

Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980216-5

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980216-5

7 January 2021

Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980216-5

7 January 2021

Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980216-5

7 January 2021

Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980216-5

7 January 2021

A double-blind study to compare the efficacy, tolerance and safety of two doses of the angiotensin converting enzyme inhibitor ramipril with placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980216-5

7 January 2021

Comparative double-blind study of ramipril and captopril in mild to moderate essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980216-5

7 January 2021

A multi-centre comparative study between ramipril and enalapril in patients with mild to moderate essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980216-5

7 January 2021

Recommendations for routine blood pressure measurement by indirect cuff sphygmomanometry. American Society of Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980216-5

7 January 2021

Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980216-5

7 January 2021

Postmarketing surveillance of captopril for hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980216-5

7 January 2021

Underutilization of antihypertensive drugs and associated hospitalization

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980216-5

7 January 2021

Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980216-5

7 January 2021

10.1016/S0149-2918(96)80216-5

Identifiers

DOI

1 reference

4 November 2017

1 reference